For 2020, we are excited to finally offer our industry-first CBG-rich lineup to farmers across the nation. Three years of intensive laboratory and field testing have proven our varieties capable of producing flower with upwards of 20% CBG, but also remain well below 0.3% total THC.  This means plants that will pass compliance tests in ANY state with a hemp program, even under new federal guidelines.   

Our initial offerings, Stem Cell and White CBG, are both field-ready varieties that grow, produce, and finish as reliably as our early CBD lines that so many have grown to trust. Their vigor means rapid growth and strength with minimal necessary field inputs. 

If you are new to CBG, it is an emerging cannabinoid in the industry, showing promising results in treating a lengthy list of medical conditions beyond even that of CBD.  Check out this article in Forbes Magazine for some current research.  Additionally, unlike CBD, it is not currently in use as a prescribe-able drug and therefore the FDA cannot prevent its inclusion in products. 

While CBG is slowly gaining momentum with the public, it is already highly sought after by extractors. Prices for CBG-rich biomass are consistently fetching 5 times, or more, over that offered for CBD for our farmers who trialed our varieties in 2019. Manicured flower prices are said to be 2 to 5 times higher. We can’t guarantee these prices in the future, but we know the demand is growing and we are (after 3 years of internal use trials) confident it will eventually benefit more people than CBD.